Navigation Links
Oncolytics Biotech, Inc. announces publication of research
Date:1/7/2008

CALGARY, AB, January 7, 2008 -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) (Oncolytics) reported today that a research group led by Dr. Richard Vile of the Mayo Clinic College of Medicine in Rochester, Minnesota, published the results of its work testing the antitumor efficacy and safety of various combinations of reovirus and cyclophosphamide in vivo. The paper, entitled Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus appears online in the January 1, 2008 issue of Clinical Cancer Research.

This exciting Mayo Clinic work supported the initiation of our combination REOLYSIN and cyclophosphamide clinical trial, recently approved by the U.K. health authorities, said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics.

The purpose of the research study was to investigate whether it was possible to use cyclophosphamide, an immune modulator, to enhance the delivery and replication of the reovirus when delivered intravenously. After testing various doses and dosing regimens of reovirus and cyclophosphamide in mice, a metronomic dosing regimen was developed that resulted in increased survival, high levels of reovirus recovered from regressing tumors, levels of neutralizing antibodies that were protective, and only very mild toxicities. The data support investigation in human clinical trials of the use of cyclophosphamide prior to systemic reovirus administration to modulate, but not ablate, the immune system.


'/>"/>

Contact: Cathy Ward
cathy.ward@oncolytics.ca
403-670-7377
Oncolytics Biotech Inc.
Source:Eurekalert

Page: 1

Related biology news :

1. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
2. LaserCard Corporation Announces Expansion of Middle East Project
3. BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution
4. Balzan Foundation announces 2007 winners
5. The American Society of Plant Biologists announces 2007 awards
6. ASPB announces Summer Undergraduate Research Fellowship 2007 recipients
7. NIST announces 56 new awards for innovative technology research and development
8. Titanium Group Announces Contract With Haitong Securities
9. Measurement Specialties, Inc. Announces Impact of German Business Tax Reform 2008 Resulting in Lower Combined German Tax Rate - Impacts 2Q08 Reported Financial Results
10. FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change
11. HGS announces positive Phase 2 LymphoStat-B at ACR meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology: